An internal standard for the quantification of istradefylline
Related Products
Unlabeled Version(s)
22958Istradefylline
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Istradefylline-13C-d3

Item No. 31240

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-(methyl-13C-d3)-3,7-dihydro-1H-purine-2,6-dione
Molecular Formula
C19[13C]H21D3N4O4
Formula Weight
388.5
Purity
≥99% deuterated forms (d1-d3)
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMSO: solubleMethanol: soluble
SMILES
CCN(C(N1CC)=O)C2=C(N([13C]([2H])([2H])[2H])C(/C=C/C3=CC=C(OC)C(OC)=C3)=N2)C1=O
InChi Code
InChI=1S/C20H24N4O4/c1-6-23-18-17(19(25)24(7-2)20(23)26)22(3)16(21-18)11-9-13-8-10-14(27-4)15(12-13)28-5/h8-12H,6-7H2,1-5H3/b11-9+/i3+1D3
InChi Key
IQVRBWUUXZMOPW-YGJBQVCASA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $388

    Add
    Product Description

    Istradefylline-13C-d3 is intended for use as an internal standard for the quantification of istradefylline (Item No. 22958) by GC- or LC-MS. Istradefylline is an adenosine receptor 2A (A2A) antagonist (Ki = 2.2 nM in a radioligand binding assay).1 In vivo, istradefylline inhibits catalepsy induced by haloperidol (Item No. 12014) with an ED50 value of 0.23 mg/kg in rats. Oral administration of istradefylline alleviates postural defects in a dose-dependent manner without inducing dyskinesias or hyperactivity in an MPTP-induced marmoset model of Parkinson's disease.2 It also decreases bradykinesias induced by L-DOPA (Item No. 13248) and improves attentional and working memory deficits in an MPTP-induced macaque model of Parkinson's disease.3 Formulations containing istradefylline are used to extend on-time in Parkinson's disease patients experiencing motor fluctuations.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Shimada, J., Nobuaki, K., Nonaka, H., et al. Adenosine A2A antagonists with potent anti-cataleptic activity. Bioorg. Med. Chem. Lett. 7(18), 2349-2352 (1997).

    2. Kanda, T., Jackson, M.J., Smith, L.A., et al. Adenosine A2A antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol. 43(4), 507-513 (1998).

    3. Ko, W.K.D., Camus, S.M., Li, Q., et al. An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models. Neuropharmacology 100(Pt. A), 48-58 (2016).